Sample size calculation in oncology trials quality of reporting and implications for clinical cancer research

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 6, 2015, Pages 570-574

  Bariani, Giovanni M ^a   De Celis Ferrari, Anezka C R ^a   Precivale, Maristela ^b   Arai, Roberto ^c   Saad, Everardo D ^d   Riechelmann, Rachel P ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PGS Statistics ^*  (Brazil)

^c Oncology Center Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^d Dendrix Research   (Brazil)

Author keywords

Randomized clinical trial; Sample size calculation; Study design

Indexed keywords

CALCULATION; CANCER RESEARCH; CONTROLLED CLINICAL TRIAL; ERROR; EXPERIMENTAL MODEL; HUMAN; ONCOLOGY; PHASE 3 CLINICAL TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; STUDY DESIGN; SYSTEMATIC REVIEW; MEDICAL RESEARCH; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); RESEARCH; STANDARDS; STATISTICS; STATISTICS AND NUMERICAL DATA;

BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RESEARCH REPORT; SAMPLE SIZE; STATISTICS AS TOPIC;

EID: 84948574986     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000436085.23342.2d     Document Type: Article

References (22)

1. Simera I, Kirtley S, Altman DG. Reporting clinical research: guidance to encourage accurate and transparent research reporting. Maturitas. 2012; 72: 84-87.
2. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005; 365: 1348-1353.
3. Altman DG. Statistics and ethics in medical research: III How large a sample? Br Med J. 1980; 281: 1336-1338.
4. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002; 288: 358-362.
5. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340: c332.
6. Charles P, Giraudeau B, Dechartres A, et al. Reporting of sample size calculation in randomised controlled trials: review. BMJ. 2009; 338: b1732.
7. Abdul Latif L, Daud Amadera JE, Pimentel D, et al. Sample size calculation in physical medicine and rehabilitation: a systematic review of reporting, characteristics, and results in randomized controlled trials. Arch Phys Med Rehabil. 2011; 92: 306-315.
8. Toulmonde M, Bellera C, Mathoulin-Pelissier S, et al. Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol. 2011; 29: 1204-1209.
9. Hui D, Arthur J, Dalal S, et al. Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials. Support Care Cancer. 2012; 20: 1779-1785.
10. Meinert CL. Clinical trials: design, conduct, and analysis. New York: Oxford University Press; 1986.
11. Chan AW, Hrobjartsson A, Jorgensen KJ, et al. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008; 337: a2299.
12. Fleming TR, Odem-Davis K, Rothmann MD, et al. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials. 2011; 8: 432-439.
13. Altman DG, Moher D, Schulz KF. Peer review of statistics in medical research. Reporting power calculations is important. BMJ. 2002; 325: 491, author reply.
14. The New England Journal of Medicine: Author Center Supplementary Appendix. Available at: http://wwwnejmorg/page/authorcenter/supplementary-appendix. Accessed March 1, 2013.
15. Ocana A, Amir E, Seruga B. Clinical research: show us the data. J Clin Oncol. 2011; 29: 1099-1100.
16. Royall RM. The effect of sample size on the meaning of significance tests. Am Stat. 1986; 40: 313-315.
17. Bedard P, Krzyzanowska MK, Pintilie M, et al. Statistical power of negative randomized clinical trials (RCTs) presented at the American Society of Clinical Oncology (ASCO) Annual Meetings. J Clin Oncol. 2007; 25: 3482-3487, (suppl; abstr 6516).
18. Bagai RK, Dowlati A. Evolution of statistical methodology and design of phase II/III clinical trials in non-small cell lung cancer (NSCLC). J Clin Oncol. 2006; 24, (suppl; abstr 7108).
19. Saad ED, Buyse M. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. Acta Oncol. 2012; 51: 890-896.
20. Gan HK, You B, Pond GR, et al. Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. J Clin Oncol. 2010; 28, (suppl; abstr 6122).
21. You B, Gan HK, Pond G, et al. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol. 2012; 30: 210-216.
22. European Science Foundation. Implementation of medical research in clinical practice: an ESF forward look, 2011. Available at: http://www.esf.org/publications.html?tx-ccdamdl-pi1%5Bpointer%5D=1& cHash=5facba551e13516e3a4b9154f8680f35. Accessed March 1, 2013.